Allergan Aesthetics has secured EU approval for Boey (trenibotulinumtoxinE), positioning it as the first and only rapid-onset, short-duration neurotoxin for temporary glabellar frown-line improvement in adults. The product differentiates itself through faster onset—results appearing within days rather than the typical 7–14 days for botulinum toxin type A—and shorter duration, making it a distinct clinical profile within the neuromodulator category.
Injectables
AbbVie's Boey Wins EU Approval for Frown Lines — First Rapid-Onset Botox Alternative
Allergan Aesthetics' trenibotulinumtoxinE gains European clearance as a faster-acting, shorter-duration neuromodulator.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
First and only rapid-onset, short-duration neurotoxin for frown lines in Europe.
For medspa owners, Boey represents new competitive pressure in the toxin market. While AbbVie maintains dominance through Botox and Dysport, this entry signals intent to capture patients seeking quicker results and shorter commitment windows. The mechanism—a different botulinum toxin serotype—carries different diffusion and unit-to-effect ratios, requiring practice retraining and potentially new pricing strategies. EU approval is the regulatory foothold; US FDA clearance remains the material gate for North American practices.
Source: original report ↗
Frequently asked questions
What is Boey and how does it differ from Botox?
Boey (trenibotulinumtoxinE) is a botulinum toxin type E neuromodulator that works faster than traditional Botox, with results visible within days rather than 7–14 days. It also has a shorter duration of effect, making it ideal for patients who want quicker results or prefer shorter commitment windows between treatments.
Is Boey approved in the United States?
Boey has received EU approval but has not yet obtained FDA clearance in the US. US FDA approval remains the critical regulatory milestone for North American medspa practices to offer this treatment.
What do medspa owners need to know about Boey's unit-to-effect ratio?
Boey uses a different botulinum toxin serotype than Botox and Dysport, which means it has different diffusion patterns and unit-to-effect ratios. Practices will need to retrain staff on proper dosing and injection techniques to ensure safe and effective results.
How will Boey affect medspa pricing and competition?
Boey's faster onset and shorter duration create a new market segment that may command premium pricing for patients seeking quicker results. However, it also introduces competitive pressure in the neuromodulator market, potentially requiring practices to adjust their pricing strategies and service offerings.
What is the clinical indication for Boey?
Boey is approved for temporary improvement of glabellar frown lines (the lines between the eyebrows) in adults. Its primary differentiator is rapid onset and shorter duration compared to standard botulinum toxin type A products.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.